Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018

Details for Mechanism ID: 17293
Country/Region: Tanzania
Year: 2016
Main Partner: Management and Development for Health
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $18,958,980 Additional Pipeline Funding: $13,033,510

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $3,115,969
Care: TB/HIV (HVTB) $642,812
Care: Pediatric Care and Support (PDCS) $213,653
Laboratory Infrastructure (HLAB) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Testing: HIV Testing and Counseling (HVCT) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $645,132
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $3,115,894
Treatment: Adult Treatment (HTXS) $10,280,789
Treatment: Pediatric Treatment (PDTX) $944,731
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV Age/Sex: <10 Female 2017 2,671
GEND_GBV Age/Sex: <10 Male 2017 2,432
GEND_GBV Age/Sex: 10-14 Female 2017 3,989
GEND_GBV Age/Sex: 10-14 Male 2017 2,980
GEND_GBV Age/Sex: 15-19 Female 2017 2,236
GEND_GBV Age/Sex: 15-19 male 2017 2,166
GEND_GBV Age/Sex: 20-24 Female 2017 1,701
GEND_GBV Age/Sex: 20-24 Male 2017 1,407
GEND_GBV Age/Sex: 25-49 Female 2017 2,142
GEND_GBV Age/Sex: 25-49 Male 2017 1,807
GEND_GBV Age/Sex: 50+ Female 2017 266
GEND_GBV Age/Sex: 50+ Male 2017 217
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 1,021
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 16,005
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 8,009
GEND_GBV Number of people receiving post-GBV care 2017 24,014
GEND_GBV Sum of Age/Sex Disaggregates 2017 12,072
HTS_TST Age/sex: <1 2017 5,979
HTS_TST Age/sex: 1-9 2017 14,355
HTS_TST Age/sex: 10-14 Female 2017 5,905
HTS_TST Age/sex: 10-14 Male 2017 3,741
HTS_TST Age/sex: 15-19 Female 2017 8,960
HTS_TST Age/sex: 15-19 Male 2017 6,837
HTS_TST Age/sex: 20-24 Female 2017 17,957
HTS_TST Age/sex: 20-24 Male 2017 689
HTS_TST Age/sex: 25-49 Female 2017 75,999
HTS_TST Age/sex: 25-49 Male 2017 32,152
HTS_TST Age/sex: 50+ Female 2017 6,235
HTS_TST Age/sex: 50+ Male 2017 8,289
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 125,247
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 156,460
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 496,462
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 259,439
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 1,224,706
HTS_TST Service Delivery Point (Facility): Inpatient 2017 55,219
HTS_TST Service Delivery Point (Facility): Other PITC 2017 50,006
HTS_TST Service Delivery Point (Facility): Outpatient 2017 584,723
HTS_TST Service Delivery Point (Facility): Pediatric 2017 270,805
HTS_TST Service Delivery Point (Facility): PMTCT 2017 206,508
HTS_TST Service Delivery Point (Facility): VMMC 2017 57,445
HTS_TST Sum of Age/Sex disaggregates 2017 166,764
HTS_TST Sum of Aggregated Age/Sex <15 2017 281,707
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 755,901
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 1,037,608
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 279
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 177
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 536
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 478
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 1,088
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 44
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 4,587
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 2,241
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 376
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 581
HTS_TST_POS Test Result by Age: Positive: <1 2017 285
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 677
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 2,147
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 2,186
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 27,653
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 14,728
KP_MAT Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months 2017 2,606
KP_MAT Sex: Female 2017 1,302
KP_MAT Sex: Male 2017 1,304
KP_MAT Sum of Sex disaggregates 2017 2,606
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 44
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 44
LAB_PT CD4: Number of laboratories that perform this testing 2017 44
LAB_PT Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 2
LAB_PT Early infant diagnostics: Number of laboratories that participate in this PT program 2017 2
LAB_PT Early infant diagnostics: Number of laboratories that perform this testing 2017 2
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 162
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 153
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 162
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 153
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 161
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 153
LAB_PT HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 2
LAB_PT HIV viral load: Number of laboratories that participate in this PT program 2017 2
LAB_PT HIV viral load: Number of laboratories that perform this testing 2017 2
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 26
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 58
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 26
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 58
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 27
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 58
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program 2017 1
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that perform this testing 2017 1
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 8
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program 2017 8
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing 2017 8
PMTCT_ART Already on ART at beginning of current pregnancy 2017 3,783
PMTCT_ART New on ART 2017 8,389
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 198,328
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 10,356
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 1,810
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 57
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 136
PMTCT_EID Sum of Infant Age disaggregates 2017 12,166
PMTCT_STAT By: Known positives at entry 2017 3,973
PMTCT_STAT By: Number of new positives identified 2017 8,830
PMTCT_STAT Number of new ANC and L&D clients 2017 208,779
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 198,328
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 15-19 2017 62
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 20-24 2017 207
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 25-49 2017 848
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 50+ 2017 9
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: <15 2017 8
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 15-19 2017 139
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 20-24 2017 398
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 25-49 2017 1,591
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 50+ 2017 22
PMTCT_STAT Sum of Positives Status disaggregates 2017 12,803
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15 2017 287
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15-19 2017 2,448
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 20-24 2017 7,421
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 25-49 2017 32,817
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 50+ 2017 552
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 3,790
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 72
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 3,305
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 413
TB_SCREENDX Screen Result: Screened Positive for TB 2017 3,790
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 160,123
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 60,146
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 6,585
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 6,221
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 233,075
TX_CURR Age/Sex: <1 2017 40
TX_CURR Age/Sex: <1-9 2017 2,343
TX_CURR Age/Sex: 10-14 Female 2017 509
TX_CURR Age/Sex: 10-14 Male 2017 495
TX_CURR Age/Sex: 15-19 Female 2017 2,669
TX_CURR Age/Sex: 15-19 Male 2017 1,003
TX_CURR Age/Sex: 20-24 Female 2017 7,121
TX_CURR Age/Sex: 20-24 Male 2017 120
TX_CURR Age/Sex: 25-49 Female 2017 32,432
TX_CURR Age/Sex: 25-49 Male 2017 5,054
TX_CURR Age/Sex: 50+ Female 2017 2,474
TX_CURR Age/Sex: 50+ Male 2017 1,479
TX_CURR Aggregated Age/Sex: <15 Female 2017 5,054
TX_CURR Aggregated Age/Sex: <15 Male 2017 5,409
TX_CURR Aggregated Age/Sex: 15+ Female 2017 144,598
TX_CURR Aggregated Age/Sex: 15+ Male 2017 34,537
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 245,337
TX_CURR Sum of age/sex disaggregates 2017 3,672
TX_CURR Sum of Aggregated Age/Sex <15 2017 10,463
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 179,135
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 189,598
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 2,608
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 2,693
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 63,792
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 16,467
TX_NEW By Age/Sex: <1 2017 40
TX_NEW By Age/Sex: 1-9 2017 794
TX_NEW By Age/Sex: 10-14 Female 2017 385
TX_NEW By Age/Sex: 10-14 Male 2017 177
TX_NEW By Age/Sex: 15-19 Female 2017 1,500
TX_NEW By Age/Sex: 15-19 Male 2017 515
TX_NEW By Age/Sex: 20-24 Female 2017 3,010
TX_NEW By Age/Sex: 20-24 Male 2017 49
TX_NEW By Age/Sex: 25-49 Female 2017 12,743
TX_NEW By Age/Sex: 25-49 Male 2017 2,419
TX_NEW By Age/Sex: 50+ Female 2017 1,042
TX_NEW By Age/Sex: 50+ Male 2017 625
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 108,859
TX_NEW Sum of Age/Sex disaggregates 2017 22,465
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 85,560
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 184,915
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 166,799
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 4,941
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 4,969
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 126,631
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 30,258
TX_PVLS Numerator: Indication: Routine 2017 98,212
TX_PVLS Numerator: Indication: Targeted 2017 68,587
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 5,458
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 5,479
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 140,409
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 33,569
TX_PVLS_den Denominator: Indication: Routine 2017 108,860
TX_PVLS_den Denominator: Indication: Targeted 2017 76,055
TX_RET Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 6
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 138
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 67
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 26
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 256
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 88
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 524
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,199
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 416
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 179
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 105
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 551
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 510
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 11,942
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 3,726
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 20,738
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 27,647
TX_RET_den Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 177
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 86
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 33
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 341
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 111
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 691
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,925
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 557
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 235
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 140
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 739
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 682
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 15,947
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 4,971
VMMC_CIRC By Age: 10-14 2017 28,723
VMMC_CIRC By Age: 15-19 2017 15,109
VMMC_CIRC By Age: 20-24 2017 6,538
VMMC_CIRC By Age: 25-29 2017 7,075
VMMC_CIRC By circumcision technique: Surgical VMMC 2017 57,445
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2017 57,445
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2017 57,445
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2017 50,370
Cross Cutting Budget Categories and Known Amounts Total: $2,640,000
Human Resources for Health $800,000
Food and Nutrition: Policy, Tools, and Service Delivery $200,000
Key Populations: MSM and TG $70,000
Training of health workers and community outreach workers
Monitoring and evaluation of MSM/TG programs
Key Populations: Sex Workers $70,000
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Monitoring and evaluation of SW programs
Gender: Gender Based Violence (GBV) $1,000,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Gender: Gender Equality $500,000
Increase gender-equitable access to income and productive resources, including education
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation